Kirkland & Ellis LLP structures every kind of deal in the healthcare and life sciences industries, from large transactional mandates to day-to-day regulatory matters for clients in various areas, such as clinical research, sales and marketing, compliance and market exclusivities. Bringing a breadth of expertise to the New York-based team, Devora Allon has a particular focus on antitrust, product liability and other commercial disputes, while Jay Lefkowitz also specialises in antitrust and product liability, but concentrates on litigation against the FDA and False Claims Act matters. Alongside them, Jeanna Wacker covers patent litigation for clients in the pharma, biotech, chemical and medical device industries, representing both plaintiffs and defendants at all stages of litigation.
Legal 500 Editorial commentary
Accolades
Client satisfaction: Lawyer & team quality
Client satisfaction: Sector knowledge
Testimonials
Collated independently by Legal 500 research team.
‘The firm is consistently accessible and responsive.'
‘The Kirkland team are market leaders in M&A within the drug development/life sciences space. They are the go-to firm for such transactions.’
Work highlights
Representing Gilead Sciences, Inc. in a qui tam action.
Representing Sun Pharma and its Ranbaxy subsidiaries in a putative class action antitrust lawsuit seeking upward of $10 billion in damages.
Awarded summary judgment on all claims in a sweeping False Claims Act (FCA) case alleging a nationwide, 15-year scheme to promote Botox off-label and with kickbacks.
Lawyers
Leading partners
The strongest partners in their field, leading on market-leading deals and endorsed by peers and clients alike.
Other key lawyers
Devora Allon; Jeanna Wacker; Jay Lefkowitz